Scarica l'app Stockscreener
203.10
1.16%
-2.39
Pre-mercato:
203.80
0.70
+0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
About Axsome Therapeutics, Inc. rStock - Coinbase
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
Migraine Market: Pharma Pipeline Fuels Rapid Expansion by 2036 – DelveInsight | Eli Lilly, Teva Pharma, Axsome Therapeutics, AEON Biopharma, Charleston Lab, Amgen, Teva Pharma, Anne Lindblad - Barchart.com
AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’ - Stocktwits
Axsome Therapeutics (NASDAQ:AXSM) Trading Up 7%Should You Buy? - MarketBeat
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN) - The Globe and Mail
Axsome Therapeutics, Inc. $AXSM Shares Bought by California State Teachers Retirement System - MarketBeat
Axsome at cantor healthcare conference: auvelity growth accelerates By Investing.com - Investing.com South Africa
Transcript : Axsome Therapeutics, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 02 - marketscreener.com
AXSM: AUVELITY's commercial expansion and deep pipeline position the company for strong near-term growth - TradingView
Axsome at cantor healthcare conference: auvelity growth accelerates - investing.com
AXSM: AUVELITY's rapid growth and robust CNS pipeline position the company for significant expansion - TradingView
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Axsome Therapeutics Inc (19X) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc (19X) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics (AXSM) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Axsome Therapeutics at Wells Fargo conference: growth broadens By Investing.com - Investing.com South Africa
Axsome Therapeutics Inc (19X) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc (19X) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Axsome reports strong growth for its CNS drugs ... - Pluang
Axsome Therapeutics Inc (19X) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc (19X) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
AXSM: AUVELITY's growth accelerates with new indications and strong pipeline progress, supported by solid financials - TradingView
Transcript : Axsome Therapeutics, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 03 - marketscreener.com
Axsome Therapeutics at Wells Fargo conference: growth broadens - investing.com
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
The Technical Signals Behind (AXSM) That Institutions Follow - Stock Traders Daily
Hsbc Holdings PLC Sells 12,653 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Inc (AXSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Is Axsome Therapeutics (NASDAQ:AXSM) Entering A Turning Point? - Kalkine Media
33,554 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Readystate Asset Management LP - MarketBeat
Axsome Therapeutics (AXSM) Investor Outlook: Unveiling a 38% Upside Potential Amidst Rapid Growth in CNS Therapies - DirectorsTalk Interviews
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Seven Fleet Capital Management LP Grows Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
12,293 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Public Employees Retirement System of Ohio - MarketBeat
Corient Private Wealth LP Makes New $1.26 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome therapeutics COO Mark Jacobson sells $2.08m of company stock - Investing.com Nigeria
Axsome Therapeutics, Inc. $AXSM Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Axsome Therapeutics (AXSM) Institutional Ownership 2026 - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) COO Sells $2,086,500.00 in Stock - MarketBeat
Axsome Therapeutics (AXSM) COO sells 10,000 shares in pre-set trading plan - Stock Titan
Planned $2.1M Axsome Therapeutics (AXSM) stock sale set under pre-arranged trading plan - Stock Titan
Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $256 - moomoo.com
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), BioMarin Pharmaceutical (BMRN) and Envista Holdings (NVST) - The Globe and Mail
Axsome Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Legal & General Group Plc Makes New $8.10 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Van ECK Associates Corp Has $7.17 Million Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
20,091 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Alyeska Investment Group L.P. - MarketBeat
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation - Yahoo Finance
Axsome Therapeutics' Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation, RBC Says - marketscreener.com
Wellington Management Group LLP Has $160.06 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Insider Ups Holding During Year - Moomoo
HC Wainwright Reaffirms "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Axsome doses first patient in phase 3 smoking cessation trial - Investing.com
Axsome Therapeutics Starts Phase 3 Trial of AXS-05 for Smoking Cessation - marketscreener.com
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation - Yahoo Finance
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: A Biotech Gem with 43% Upside Potential - DirectorsTalk Interviews
Jupiter Topco LLC Makes New Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Jefferies Financial Group Inc. Invests $6.27 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
0.14%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):